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I. Introduction
Although considerable improvement has occurred in the process of care for patients with ST-elevation myocardial infarction (STEMI), room for improvement exists. [1] [2] [3] The purpose of the present guideline is to focus on the numerous advances in the diagnosis and management of patients with STEMI since 1999. This is reflected in the changed name of the guideline: "ACC/ AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction." The final recommendations for indications for a diagnostic procedure, a particular therapy, or an intervention in patients with STEMI summarize both clinical evidence and expert opinion ( Table 1) . To provide clinicians with a set of recommendations that can easily be translated into the practice of caring for patients with STEMI, this guideline is organized around the chronology of the interface between the patient and the clinician. The full guideline is available at http://www.acc.org/clinical/guidelines/stemi/index.htm.
II. Pathology

A. Epidemiology
STEMI continues to be a significant public health problem in industrialized countries and is becoming an increasingly significant problem in developing countries. 4 Although the exact incidence is difficult to ascertain, using first-listed and secondary hospital discharge data, there were 1 680 000 unique discharges for ACS in 2001. 5 Applying the conservative estimate of 30% of the ACS patients who have STEMI from the National Registry of Myocardial Infarction-4 [NRMI-4], 5a we estimate 500 000 STEMI events per year in the U.S. This writing committee strongly endorses several public health campaigns that are likely to contribute to a reduction in the incidence of and fatality from STEMI in the future and additional research of new strategies for the management of STEMI patients in the community. 6 -13 
III. Management Before STEMI
A. Identification of Patients at Risk of STEMI
B. Patient Education for Early Recognition and
Response to STEMI fear of potential embarrassment (Level of Evidence: C) d. A plan for appropriate recognition and response to a potential acute cardiac event that includes the phone number to access emergency medical services (EMS), generally 9-1-1. 15 (Level of Evidence: C) 3. Healthcare providers should instruct patients for whom nitroglycerin has been prescribed previously to take ONE nitroglycerin dose sublingually in response to chest discomfort/pain. If chest discomfort/pain is unimproved or worsening 5 minutes after 1 sublingual nitroglycerin dose has been taken, it is recommended that the patient or family member/friend call 9-1-1 immediately to access EMS. (Level of Evidence: C)
Morbidity and mortality due to STEMI can be reduced significantly if patients and bystanders recognize symptoms early, activate the EMS system, and thereby shorten the time to definitive treatment. Patients with possible symptoms of STEMI should be transported to the hospital by ambulance rather than by friends or relatives because there is a significant association between arrival at the emergency department (ED) by ambulance and early reperfusion therapy. 16 -19 Although the traditional recommendation is for patients to take 1 nitroglycerin dose sublingually, 5 minutes apart, for up to 3 doses before †The ACC/AHA Task Force on Practice Guidelines recently provided a list of suggested phrases to use when writing recommendations. All recommendations in the STEMI guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers' comprehension of the guidelines and will allow queries at the individual recommendation level. "Estimate of Certainty (Precision) of Treatment of Effect" calling for emergency evaluation, this recommendation has been modified by the writing committee to encourage earlier contacting of EMS by patients with symptoms suggestive of STEMI. 20, 21 The links in the chain include early access (recognition of the problem and activation of the EMS system by a bystander), early CPR, early defibrillation for patients who need it, and early ACLS. Early access to EMS is promoted by a 9-1-1 system currently available to more than 90% of the US population. To minimize time to treatment, particularly for cardiopulmonary arrest, many communities allow volunteer and/or paid firefighters and other first-aid providers to function as first responders, providing CPR and, increasingly, early defibrillation using automated external defibrillators (AEDs) until emergency medical technicians and paramedics arrive. Most cities and larger suburban areas provide EMS ambulance services with providers from the fire department, a private ambulance company, and/or volunteers. It is reasonable for physicians to encourage the prehospital administration of aspirin via EMS personnel (ie, EMS dispatchers and providers) in patients with symptoms suggestive of STEMI unless its use is contraindicated. 22 For patients who have ECG evidence of STEMI, it is reasonable that paramedics review a reperfusion checklist and relay the ECG and checklist findings to a predetermined medical control facility and/or receiving hospital.
IV. Onset of STEMI A. Out-of-Hospital Cardiac Arrest
V. Prehospital Issues
A. Emergency Medical Services Systems
B. Prehospital Chest Pain Evaluation and Treatment
C. Prehospital Fibrinolysis
Class IIa 1. Establishment of a prehospital fibrinolysis protocol is reasonable in 1) settings in which physicians are present in the ambulance or in 2) well-organized EMS systems with full-time paramedics who have 12-lead ECGs in the field with transmission capability, paramedic initial and ongoing training in ECG interpretation and STEMI treatment, online medical command, a medical director with training/experience in STEMI management, and an ongoing continuous quality-improvement program.
(Level of Evidence: B)
Randomized controlled trials of fibrinolytic therapy have demonstrated the benefit of initiating fibrinolytic therapy as early as possible after onset of ischemic-type chest discomfort ( Figure 1 ). [23] [24] [25] It appears reasonable to expect that if fibrinolytic therapy could be started at the time of prehospital evaluation, a greater number of lives could be saved. Prehospital fibrinolysis is reasonable in those settings in which physicians are present in the ambulance or prehospital transport times are more than 60 minutes in high-volume (more than 25,000 runs per year) EMS systems. 26 Other considerations for implementing a prehospital fibrinolytic service include the ability to transmit ECGs, paramedic initial and ongoing training in ECG interpretation and myocardial infarction (MI) treatment, online medical command, a medical director with training/experience in management of STEMI, and full-time paramedics. 27 Every community should have a written protocol that guides EMS system personnel in determining where to take patients with suspected or confirmed STEMI. Active involvement of local healthcare providers, particularly cardiologists and emergency physicians, is needed to formulate local EMS destination protocols for these patients. In general, patients with suspected STEMI should be taken to the nearest appropriate hospital. However, patients with STEMI and shock are an exception to this general rule. Whenever possible, STEMI patients less than 75 years of age with shock should be transferred to facilities capable of cardiac catheterization and rapid revascularization (PCI or CABG). On the basis of observations in the SHOCK Trial Registry and other registries, it is reasonable to extend such considerations of transfer to invasive centers for elderly patients with shock (see VII.F.5 and Section 7.6.5 of the full-text guidelines). Patients with STEMI who have contraindications to fibrinolytic therapy should be brought immediately or secondarily transferred promptly (ie, primary-receiving hospital door-to-departure time less than 30 minutes) to facilities capable of cardiac catheterization and rapid revascularization (PCI or CABG). 
D. Prehospital Destination Protocols
VI. Initial Recognition and Management in the Emergency Department
A. Optimal Strategies for Emergency Department Triage
B. Initial Patient Evaluation
Class I 1. The delay from patient contact with the healthcare system (typically, arrival at the ED or contact with paramedics) to initiation of fibrinolytic therapy should be less than 30 minutes. Alternatively, if PCI is chosen, the delay from patient contact with the healthcare system (typically, arrival at the ED or contact with paramedics) to balloon inflation should be less than 90 minutes. (Level of Evidence: B) 2. The choice of initial STEMI treatment should be made by the emergency medicine physician on duty based on a predetermined, institution-specific, written protocol that is a collaborative effort of cardiologists (both those involved in coronary care unit management and interventionalists), emergency physicians, primary care physicians, nurses, and other appropriate personnel.
For cases in which the initial diagnosis and treatment plan is unclear to the emergency physician or is not covered directly by the agreed-on protocol, immediate cardiology consultation is advisable. (Level of Evidence: C)
Regardless of the approach used, all patients presenting to the ED with chest discomfort or other symptoms suggestive of STEMI or unstable angina should be considered highpriority triage cases and should be evaluated and treated based on a predetermined, institution-specific chest pain protocol. The goal for patients with STEMI should be to Figure 1 . Options for transportation of STEMI patients and initial reperfusion treatment. Panel A, Patient transported by EMS after calling 9-1-1: Reperfusion in patients with STEMI can be accomplished by the pharmacological (fibrinolysis) or catheter-based (primary PCI) approaches. Implementation of these strategies varies based on the mode of transportation of the patient and capabilities at the receiving hospital. Transport time to the hospital is variable from case to case, but the goal is to keep total ischemic time within 120 minutes. There are 3 possibilities: (1) If EMS has fibrinolytic capability and the patient qualifies for therapy, prehospital fibrinolysis should be started within 30 minutes of EMS arrival on scene. (2) If EMS is not capable of administering prehospital fibrinolysis and the patient is transported to a non-PCI-capable hospital, the hospital door-to-needle time should be within 30 minutes for patients in whom fibrinolysis is indicated. (3) If EMS is not capable of administering prehospital fibrinolysis and the patient is transported to a PCI-capable hospital, the hospital door-to-balloon time should be within 90 minutes. Interhospital transfer: It is also appropriate to consider emergency interhospital transfer of the patient to a PCI-capable hospital for mechanical revascularization if (1) there is a contraindication to fibrinolysis; (2) PCI can be initiated promptly achieve a door-to-needle time within 30 minutes and a door-to-balloon time within 90 minutes ( Figure 1 ). 25 
History
Class
Physical Examination
Class I 1. A physical examination should be performed to aid in the diagnosis and assessment of the extent, location, and presence of complications of STEMI. (Level of Evidence: C) 2. A brief, focused, and limited neurological examination to look for evidence of prior stroke or cognitive deficits should be performed on STEMI patients before administration of fibrinolytic therapy. (Level of Evidence: C)
A brief physical examination may promote rapid triage, whereas a more detailed physical examination aids in the differential diagnosis and is useful for assessing the extent, location, and presence of complications of STEMI. The 12-lead ECG in the ED is at the center of the therapeutic decision pathway because of the strong evidence that ST-segment elevation identifies patients who benefit from reperfusion therapy. 28 
Electrocardiogram
Class
Laboratory Examinations
Class I 1. Laboratory examinations should be performed as part of the management of STEMI patients but should not delay the implementation of reperfusion therapy. (Level of Evidence: C)
In addition to serum cardiac biomarkers for cardiac damage, several routine evaluations have important implications for management of patients with STEMI. Although these studies should be ordered when the patient is first seen, therapeutic decisions should not be delayed until results are obtained because of the crucial role of time to therapy in STEMI.
Biomarkers of Cardiac Damage
Class I 1. Cardiac-specific troponins should be used as the optimum biomarkers for the evaluation of patients with STEMI who have coexistent skeletal muscle injury. (Level of Evidence: C) 2. For patients with ST elevation on the 12-lead ECG and symptoms of STEMI, reperfusion therapy should be initiated as soon as possible and is not contingent on a biomarker assay. (Level of Evidence: C)
Class IIa 1. Serial biomarker measurements can be useful to provide supportive noninvasive evidence of reperfusion of the infarct artery after fibrinolytic therapy in patients For patients with ST-segment elevation, the diagnosis of STEMI is secure; initiation of reperfusion therapy should not be delayed to wait for the results of a cardiac biomarker assay. 29 Quantitative analysis of cardiac biomarker measurements provides prognostic information and a noninvasive assessment of the likelihood that the patient has undergone successful reperfusion when fibrinolytic therapy is administered.
a. Bedside Testing for Serum Cardiac Biomarkers
Class I 1. Although handheld bedside (point-of-care) assays may be used for a qualitative assessment of the presence of an elevated level of a serum cardiac biomarker, subsequent measurements of cardiac biomarker levels should be performed with a quantitative test. (Level of Evidence: B) 2. For patients with ST elevation on the 12-lead ECG and symptoms of STEMI, reperfusion therapy should be initiated as soon as possible and is not contingent on a bedside biomarker assay. (Level of Evidence: C)
A positive bedside test should be confirmed by a conventional quantitative test. However, reperfusion therapy should not be delayed to wait for the results of a quantitative assay. Nitroglycerin may be administered to relieve ischemic pain and is clearly indicated as a vasodilator in patients with STEMI associated with left ventricular (LV) failure. Nitrates in all forms should be avoided in patients with initial systolic blood pressures less than 90 mm Hg or greater than or equal to 30 mm Hg below baseline, in patients with marked bradycardia or tachycardia, 30 and in patients with known or suspected RV infarction. In view of their marginal treatment benefits, nitrates should not be used if hypotension limits the administration of beta-blockers, which have more powerful salutary effects. In a dose of 162 mg or more, aspirin produces a rapid clinical antithrombotic effect caused by immediate and near-total inhibition of thromboxane A2 production. Aspirin now forms part of the early management of all patients with suspected STEMI and should be given promptly, and certainly within the first 24 hours, at a dose between 162 and 325 mg and continued indefinitely at a daily dose of 75 to 162 mg. 31 Although some trials have used enteric-coated aspirin for initial dosing, more rapid buccal absorption occurs with non-enteric-coated formulations. 32 
Imaging
Class I 1. Patients with STEMI should have a portable chest X-ray, but this should not delay implementation of reperfusion therapy (unless a potential contraindication, such as aortic dissection, is suspected
c. Analgesia
e. Beta-Blockers
Class I 1. Oral beta-blocker therapy should be administered promptly to those patients without a contraindication, irrespective of concomitant fibrinolytic therapy or performance of primary PCI. (Level of Evidence: A)
Class IIa 1. It is reasonable to administer IV beta-blockers promptly to STEMI patients without contraindications, especially if a tachyarrhythmia or hypertension is present. (Level of Evidence: B)
Immediate beta-blocker therapy appears to reduce the magnitude of infarction and incidence of associated complications in subjects not receiving concomitant fibrinolytic therapy, the rate of reinfarction in patients receiving fibrinolytic therapy, and the frequency of life-threatening ventricular tachyarrhythmias.
f. Reperfusion
GENERAL CONCEPTS.
Class I 1. All STEMI patients should undergo rapid evaluation for reperfusion therapy and have a reperfusion strategy implemented promptly after contact with the medical system. (Level of Evidence: A)
Evidence exists that expeditious restoration of flow in the obstructed infarct artery after the onset of symptoms in STEMI patients is a key determinant of short-and long-term outcomes regardless of whether reperfusion is accomplished by fibrinolysis or PCI. [33] [34] [35] As discussed previously (also see Section 4.1 of the fulltext guidelines), efforts should be made to shorten the time from recognition of symptoms by the patient to contact with the medical system. All healthcare providers caring for STEMI patients from the point of entry into the medical system must recognize the need for rapid triage and implementation of care in a fashion analogous to the handling of trauma patients. When considering recommendations for timely reperfusion of STEMI patients, the Writing Committee reviewed data from clinical trials, focusing particular attention on enrollment criteria for selection of patients for randomization, actual times reported in the trial report rather than simply the allowable window specified in the trial protocol, treatment effect of the reperfusion strategy on individual components of a composite primary end point (eg, mortality, recurrent nonfatal infarction), ancillary therapies (eg, antithrombin and antiplatelet agents), and the interface between fibrinolysis and referral for angiography and revascularization. When available, data from registries were also reviewed to assess the generalizability of observations from clinical trials of reperfusion to routine practice. Despite the wealth of reports on reperfusion for STEMI, it is not possible to produce a simple algorithm, given the heterogeneity of patient profiles and availability of resources in various clinical settings at various times of day. This section introduces the recommendations for an aggressive attempt to minimize the time from entry into the medical system to implementation of a reperfusion strategy using the concept of medical system goals. More detailed discussion of these goals and the issues to be considered in selecting the type of reperfusion therapy are discussed in the Selection of Reperfusion Therapy section of VI.C.1.f (Section 6.3.1.6.2 of the full-text guidelines), followed by a discussion of available resources.
The medical system goal is to facilitate rapid recognition and treatment of patients with STEMI such that door-to-needle (or medical contact-to-needle) time for initiation of fibrinolytic therapy can be achieved within 30 minutes or that door-toballoon (or medical contact-to-balloon) time for PCI can be kept under 90 minutes. These goals may not be relevant for the patients with an appropriate reason for delay, such as uncertainty about the diagnosis (particularly for the use of fibrinolytic therapy), need for the evaluation and treatment of other lifethreatening conditions (eg, respiratory failure), or delays associated with the patient's informed choice to have more time to consider the decision. In the absence of such types of circumstances, the emphasis is on having a system in place such that when a patient with STEMI presents for medical care, reperfusion therapy is able to be provided as soon as possible within these time periods. Because there is not considered to be a threshold effect for the benefit of shorter times to reperfusion, these goals should not be understood as "ideal" times but the longest times that should be considered acceptable. Systems that are able to achieve even more rapid times for patients should be encouraged. Also, this goal should not be perceived as an average performance standard but a goal of an early treatment system that every hospital should seek for every appropriate patient. SELECTION OF REPERFUSION STRATEGY. Several issues should be considered in selecting the type of reperfusion therapy:
• Time From Onset of Symptoms. Time from onset of symptoms to fibrinolytic therapy is an important predictor of MI size and patient outcome. 36 The efficacy of fibrinolytic agents in lysing thrombus diminishes with the passage of time. 37 Fibrinolytic therapy administered within the first 2 hours (especially the first hour) can occasionally abort MI and dramatically reduce mortality. 23, 38 In contrast, the ability to produce a patent infarct artery is much less dependent on symptom duration in patients undergoing PCI. Several reports claim no influence of time delay on mortality rates when PCI is performed after 2 to 3 hours of symptom duration. 39, 40 Importantly, after adjustment for baseline characteristics, time from symptom onset to balloon inflation is significantly correlated with 1-year mortality in patients undergoing primary PCI for STEMI. 41 The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology 42 and this Committee both recommend a target of medical contactto-balloon or door-to-balloon time within 90 minutes. • Risk of STEMI. Several models have been developed that assist clinicians in estimating the risk of mortality in patients with STEMI. [43] [44] [45] [46] [47] Although these models vary somewhat in the factors loaded into the risk-prediction tool and also vary with respect to statistical measures of their discriminative power (eg, C statistic), all the models provide clinicians with a means to assess the continuum of risk from STEMI. When the estimated mortality with fibrinolysis is extremely high, as is the case in patients with cardiogenic shock, compelling evidence exists that favors a PCI strategy. • Risk of Bleeding. Choice of reperfusion therapy is also affected by the patient's risk of bleeding. When both types of reperfusion are available, the higher the patient's risk of bleeding with fibrinolytic therapy, the more strongly the decision should favor PCI. If PCI is unavailable, then the benefit of pharmacological reperfusion therapy should be balanced against the risk. • Time Required for Transport to a Skilled PCI Laboratory.
The availability of interventional cardiology facilities is a key determinant of whether PCI can be provided. For facilities that can offer PCI, the literature suggests that this approach is superior to pharmacological reperfusion. 48 The trials comparing pharmacological and PCI strategies, however, were conducted before the advent of more recent pharmacological and PCI strategies. When a composite end point of death, nonfatal recurrent MI, or stroke is analyzed, much of the superiority of a PCI strategy is driven by a reduction in the rate of nonfatal recurrent MI ( Figure 2 ). 36 The rate of nonfatal recurrent MI can be influenced both by the adjunctive therapy used and by the proportion of patients who are referred for PCI when the initial attempt at fibrinolysis fails or myocardial ischemia recurs after initially successful pharmacological reperfusion.
The experience and location of the PCI laboratory also plays a role in the choice of therapy. Not all laboratories can provide prompt, high-quality primary PCI. Even centers with interventional cardiology facilities may not be able to provide the staffing required for 24-hour coverage of the catheterization laboratory. Despite staffing availability, the volume of cases in the laboratory may be insufficient for the team to acquire and maintain skills required for rapid PCI reperfusion strategies.
A decision must be made when a STEMI patient presents to a center without interventional cardiology facilities. Fibrinolytic therapy can generally be provided sooner than primary PCI. As the time delay for performing PCI increases, the mortality benefit associated with expeditiously performed primary PCI over fibrinolysis decreases. 49 Compared with a fibrin-specific lytic agent, a PCI strategy may not reduce mortality when a delay greater than 60 minutes is anticipated versus immediate administration of a lytic.
Given the current literature, it is not possible to say definitively that a particular reperfusion approach is superior for all patients, in all clinical settings, at all times of day (Danchin N; oral presentation at American Heart Association Scientific Sessions 2003, Orlando, FL, November 2003). 50 -52 The main point is that some type of reperfusion therapy should be selected for all appropriate patients with suspected STEMI. The appropriate and timely use of some reperfusion therapy is likely more important than the choice of therapy, given the current literature and the expanding array of options. Clinical circumstances in which fibrinolytic therapy is generally preferred or an invasive strategy is generally preferred are shown in Figure 3 .
Available Resources
Class I 1. STEMI patients presenting to a facility without the capability for expert, prompt intervention with primary PCI within 90 minutes of first medical contact should undergo fibrinolysis unless contraindicated. (Level of Evidence: A)
PHARMACOLOGICAL REPERFUSION.
Indications for Fibrinolytic Therapy
Class I 1. In the absence of contraindications, fibrinolytic therapy should be administered to STEMI patients with symptom onset within the prior 12 hours and ST elevation greater than 0.1 mV in at least 2 contiguous precordial leads or at least 2 adjacent limb leads. (Level of Evidence: A) 2. In the absence of contraindications, fibrinolytic therapy should be administered to STEMI patients with symptom onset within the prior 12 hours and new or presumably new LBBB. (Level of Evidence: A)
Class IIa 1. In the absence of contraindications, it is reasonable to administer fibrinolytic therapy to STEMI patients with symptom onset within the prior 12 hours and 12-lead ECG findings consistent with a true posterior MI. (Level of Evidence: C) 2. In the absence of contraindications, it is reasonable to administer fibrinolytic therapy to patients with symptoms of STEMI beginning within the prior 12 to 24 hours who have continuing ischemic symptoms and ST elevation greater than 0.1 mV in at least 2 contiguous precordial leads or at least 2 adjacent limb leads. (Level of Evidence: B)
Class III 1. Fibrinolytic therapy should not be administered to asymptomatic patients whose initial symptoms of STEMI began more than 24 hours earlier. (Level of Evidence: C) 2. Fibrinolytic therapy should not be administered to patients whose 12-lead ECG shows only ST-segment depression except if a true posterior MI is suspected. (Level of Evidence: A)
Because the benefit of fibrinolytic therapy is directly related to the time from symptom onset, treatment benefit is maximized by the earliest possible application of therapy. The constellation of clinical features that must be present (although not necessarily at the same time) to serve as an indication for fibrinolysis includes symptoms of myocardial ischemia and ST elevation greater than 0.1 mV, in at least 2 contiguous leads, or new or presumably new LBBB on the presenting ECG. 23, 54 Contraindications/Cautions Class I 1. Healthcare providers should ascertain whether the patient has neurological contraindications to fibrinolytic therapy, including any history of intracranial hemorrhage (ICH), significant closed head or facial trauma within the past 3 months, uncontrolled hypertension, or ischemic stroke within the past 3 months. (See Table 2 
for a comprehensive list.) (Level of Evidence: A) 2. STEMI patients at substantial (greater than or equal to 4%) risk of ICH should be treated with PCI rather than with fibrinolytic therapy. (See Figure 3 for further management considerations.) (Level of Evidence: A)
A detailed list of contraindications and cautions for the use of fibrinolytic therapy is shown in Table 2 .
Complications of Fibrinolytic Therapy: Neurological and Other
Class I 1. The occurrence of a change in neurological status during or after reperfusion therapy, particularly within the first 24 hours after initiation of treatment, is Figure 2 . PCI vs fibrinolysis for STEMI. Short-term (4 to 6 weeks; top left) and long-term (top right) outcomes for various end points shown are plotted for STEMI patients randomized to PCI or fibrinolysis for reperfusion in 23 trials (nϭ7739). Given the frequency of events for each end point in the 2 treatment groups, the number needed to treat (NNT) or number needed to harm (NNH) is shown for the short-term (bottom left) and long-term (bottom right) outcomes. The magnitude of treatment differences for death, nonfatal reinfarction, and stroke varies depending on whether PCI is compared with streptokinase or a fibrin-specific lytic. For example, when primary PCI is compared with alteplase and the SHOCK trial is excluded, the mortality rate is 5.5% vs 6.7% (odds ratio 0.81, 95% confidence interval 0.64 to 1.03, Pϭ0.081). 76a considered to be due to ICH until proven otherwise.
Fibrinolytic, antiplatelet, and anticoagulant therapies should be discontinued until brain imaging scan shows no evidence of ICH. (Level of Evidence: A) 2. Neurology and/or neurosurgery or hematology consultations should be obtained for STEMI patients who have ICH as dictated by clinical circumstances. (Level of Evidence: C) 3. In patients with ICH, infusions of cryoprecipitate, fresh frozen plasma, protamine, and platelets should be given, as dictated by clinical circumstances. (Level of Evidence: C)
Class IIa 1. In patients with ICH, it is reasonable to: a. Optimize blood pressure and blood glucose levels. (Level of Evidence: C) b. Reduce intracranial pressure with an infusion of mannitol, endotracheal intubation, and hyperventilation. (Level of Evidence: C) c. Consider neurosurgical evacuation of ICH. (Level of Evidence: C)
Combination Therapy With Glycoprotein IIb/IIIa Inhibitors
Class IIb 1. Combination pharmacological reperfusion with abciximab and half-dose reteplase or tenecteplase may be considered for prevention of reinfarction (Level of Evidence: A) and other complications of STEMI in selected patients: anterior location of MI, age less than 75 years, and no risk factors for bleeding. In two clinical trials of combination reperfusion, the prevention of reinfarction did not translate into a survival benefit at either 30 days or 1 year. 54a (Level of Evidence: B) 2. Combination pharmacological reperfusion with abciximab and half-dose reteplase or tenecteplase may be considered for prevention of reinfarction and other complications of STEMI in selected patients (anterior location of MI, age less than 75 years, and no risk factors for bleeding) in whom an early referral for angiography and PCI (ie, facilitated PCI) is planned. (Level of Evidence: C)
Class III 1. Combination pharmacological reperfusion with abciximab and half-dose reteplase or tenecteplase should not be given to patients aged greater than 75 years because of an increased risk of ICH. (Level of Evidence: B)
PERCUTANEOUS CORONARY INTERVENTION
Coronary Angiography
Class I
1. Diagnostic coronary angiography should be performed: Figure 3 . Assessment of reperfusion options for patients with STEMI. STEMI indicates ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; ICH, intracranial hemorrhage. *Applies to fibrin-specific agents (see Figure 15 in the full-text STEMI guidelines). †Operator experience greater than a total of 75 primary PCI cases per year. ‡Team experience greater than a total of 36 primary PCI cases per year. §This calculation implies that the estimated delay to the implementation of the invasive strategy is greater than 1 hour vs initiation of fibrinolytic therapy immediately with a fibrin-specific agent.
a. In candidates for primary or rescue PCI. (Level of Evidence: A) b. In patients with cardiogenic shock who are candidates for revascularization. (Level of Evidence: A) c. In candidates for surgical repair of ventricular septal rupture or severe mitral regurgitation (MR). (Level of Evidence: B) d. In patients with persistent hemodynamic and/or electrical instability. (Level of Evidence: C)
Class III 1. Coronary angiography should not be performed in patients with extensive comorbidities in whom the risks of revascularization are likely to outweigh the benefits. (Level of Evidence: C)
Primary PCI • Known malignant intracranial neoplasm (primary or metastatic)
Class I
General considerations: If immediately available, primary PCI should be performed in patients with
• Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3 hours
• Suspected aortic dissection
• Active bleeding or bleeding diathesis (excluding menses)
• Significant closed head or facial trauma within 3 months
Relative contraindications
• History of chronic severe, poorly controlled hypertension
• Severe uncontrolled hypertension on presentation (SBP greater than 180 mm Hg or DBP greater than 110 mm Hg) †
• History of prior ischemic stroke greater than 3 months, dementia, or known intracranial pathology not covered in contraindications
• Traumatic or prolonged (greater than 10 minutes) CPR or major surgery (less than 3 weeks)
• Recent (within 2 to 4 weeks) internal bleeding
• Noncompressible vascular punctures
• For streptokinase/anistreplase: prior exposure (more than 5 days ago) or prior allergic reaction to these agents
• Pregnancy
• Active peptic ulcer
• Current use of anticoagulants: the higher the INR, the higher the risk of bleeding AVM indicates arteriovenous malformation; SBP, systolic blood pressure; DBP, diastolic blood pressure; ICH, intracranial hemorrhage; CPR, cardiopulmonary resuscitation.
*Viewed as advisory for clinical decision making and may not be all-inclusive or definitive.
†Could be an absolute contraindication in low-risk patients with ST-elevation myocardial infarction (see Section 6.3.1.6.3.2 of the full-text guidelines).
Class IIb 1. The benefit of primary PCI for STEMI patients eligible for fibrinolysis is not well established when performed by an operator who performs fewer than 75 PCI procedures per year. (Level of Evidence: C)
Class III 1. PCI should not be performed in a noninfarct artery at the time of primary PCI in patients without hemodynamic compromise. (Level of Evidence: C) 2. Primary PCI should not be performed in asymptomatic patients more than 12 hours after onset of STEMI if they are hemodynamically and electrically stable.
(Level of Evidence: C)
Primary PCI has been compared with fibrinolytic therapy in 22 randomized clinical trials. 50, 52, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] An additional trial, SHOCK (SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?), 75 that compared medical stabilization with immediate revascularization for cardiogenic shock was included along with the above 22 trials in an overview of primary PCI versus fibrinolysis. 76 These investigations demonstrate that PCI-treated patients experience lower short-term mortality rates, less nonfatal reinfarction, and less hemorrhagic stroke than those treated by fibrinolysis but have an increased risk for major bleeding. 76 These results have been achieved in medical centers with experienced providers and under circumstances in which PCI can be performed promptly after patient presentation ( Figure 2 ). 76 Additional considerations that affect the magnitude of the difference between PCI-and fibrinolysis-treated patients include the fact that unfractionated heparin (UFH) was used as the antithrombin with fibrinolytics (as opposed to other antithrombins such as enoxaparin [see Ancillary Therapy in Section VI.C.1.f and also Section 6.3.1.6.8.1.1 of the full-text guidelines] or bivalirudin [see Section 6.3.1.6.8.1.2 of the full-text guidelines] that are associated with a reduction in the rate of recurrent MI after fibrinolysis), a smaller but still statistically significant advantage for PCI compared with a fibrin-specific lytic versus streptokinase, and variation among the PCI arms as to whether a stent was implanted or glycoprotein (GP) IIb/IIIa antagonists were administered. Figure 2 shows the short-and long-term outcomes of patients with STEMI treated by fibrinolysis versus PCI and the number of patients who need to be treated to prevent 1 event or cause 1 harmful complication when selecting PCI instead of fibrinolysis as the reperfusion strategy ( Figure 2 ). 76 Of note, when primary PCI is compared with tissue plasminogen activator (tPA) and the SHOCK trial is excluded, the mortality rate is 5.5% versus 6.7% (odds ratio 0.81%, 95% confidence interval [CI] 0.64 to 1.03, P equals 0.081. 76a There is serious and legitimate concern that a routine policy of primary PCI for patients with STEMI will result in unacceptable delays in achieving reperfusion in a substantial number of cases and produce less than optimal outcomes if performed by less-experienced operators. The mean time delay for PCI instead of fibrinolysis in the randomized studies was approximately 40 minutes. 76 Strict performance criteria must be mandated for primary PCI programs so that long door-to-balloon times and performance by low-volume or pooroutcome operators/laboratories do not occur. Interventional cardiologists and centers should strive for outcomes to include (1) medical contact-to-balloon or door-to-balloon times less than 90 minutes; (2) TIMI (Thrombolysis In Myocardial Infarction) 2/3 flow rates obtained in more than 90% of patients; (3) emergency CABG rate less than 2% among all patients undergoing the procedure; (4) actual performance of PCI in a high percentage of patients (85%) brought to the laboratory; and (5) risk-adjusted in-hospital mortality rate less than 7% in patients without cardiogenic shock. This would result in a risk-adjusted mortality rate with PCI comparable to that reported for fibrinolytic therapy in fibrinolytic-eligible patients 76 and would be consistent with previously reported registry experience. [77] [78] [79] [80] Otherwise, the focus of treatment should be the early use of fibrinolytic therapy ( Figure 2 ). 76 PCI appears to have its greatest mortality benefit in high-risk patients. In patients with cardiogenic shock, an absolute 9% reduction in 30-day mortality with coronary revascularization instead of immediate medical stabilization was reported in the SHOCK trial. 75 Time from symptom onset to reperfusion is an important predictor of patient outcome. Two studies 81, 82 have reported increasing mortality rates with increasing door-to-balloon times. Other studies have shown smaller infarct size, better LV function, and fewer complications when reperfusion occurs before PCI. [83] [84] [85] An analysis of the randomized controlled trials comparing fibrinolysis with a fibrin-specific agent versus primary PCI suggests that the mortality benefit with PCI exists when treatment is delayed by no more than 60 minutes. Mortality increases significantly with each 15-minute delay in the time between arrival and restoration of TIMI-3 flow (door-to-TIMI-3 flow time), which further underscores the importance of timely reperfusion in patients who undergo primary PCI. 86 Importantly, after adjustment for baseline characteristics, time from symptom onset to balloon inflation is significantly correlated with 1-year mortality in patients undergoing primary PCI for STEMI (relative risk equals 1.08 for each 30-minute delay from symptom onset to balloon inflation; P equals 0.04). 35, 41 Given that the medical contact-to-needle time goal within 30 minutes, this Writing Committee joins the Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology in lowering the medical contact-to-balloon or door-toballoon time goal from within 120 minutes to within 90 minutes in an attempt to maximize the benefits for reperfusion by PCI. 42 If the expected door-to-balloon time exceeds the expected doorto-needle time by more than 60 minutes, fibrinolytic treatment with a fibrin-specific agent should be considered unless it is contraindicated. This is particularly important when symptom duration is less than 3 hours but is less important with longer symptom duration, when less ischemic myocardium can be salvaged. Randomized controlled trials evaluating the outcome of PCI for patients who present with STEMI but who are ineligible for fibrinolytic therapy have not been performed. Few data are available to characterize the value of primary PCI for this subset of STEMI patients; however, the recommendations in Section IV.A (and Section 4.2 of the full-text guidelines) are applicable to these patients. Nevertheless, these patients are at increased risk for mortality, 87 and there is a general consensus that PCI is an appropriate means for achieving reperfusion in those who cannot receive fibrinolytics because of increased risk of bleeding. 88 From clinical data and expert consensus, the Committee recommends that primary PCI for acute STEMI performed at hospitals without established elective PCI programs should be restricted to those institutions capable of performing a requisite minimum number of primary PCI procedures (36 per year) with a proven plan for rapid and effective PCI and rapid access to cardiac surgery in a nearby hospital. The benefit of primary PCI is not well established for operators who perform fewer than 75 PCIs per year or in a hospital that performs fewer than 36 primary PCI procedures per year. In addition, the benefit of timely reperfusion of the infarct artery by primary PCI at sites without on-site surgery must be weighed against the small but finite risk of harm to the patient related to the time required to transfer the patient to a site with CABG surgery capabilities. 92, 93 
PRIMARY PCI IN FIBRINOLYTIC-INELIGIBLE PATIENTS
Class
INTERHOSPITAL TRANSFER FOR PRIMARY PCI
To achieve optimal results, time from the first hospital door to the balloon inflation in the second hospital should be as short as possible, with a goal of within 90 minutes. Significant reductions in door-to-balloon times might be achieved by directly transporting patients to PCI centers rather than transporting them to the nearest hospital, if interhospital transfer will subsequently be required to obtain primary PCI.
Primary Stenting
Primary stenting has been compared with primary angioplasty in 9 studies. 94 -103 There were no differences in mortality (3.0% versus 2.8%) or reinfarction (1.8% versus 2.1%) rates. However, major adverse cardiac events were reduced, driven by the reduction in subsequent target-vessel revascularization with stenting.
Preliminary reports suggest that compared with conventional bare metal stents, drug-eluting stents are not associated with increased risk when used for primary PCI in STEMI patients. 104 Postprocedure vessel patency, biomarker release, and the incidence of short-term adverse events were similar in patients receiving sirolimus (n equals 186) or bare metal (n equals 183) stents. Thirty-day event rates of death, reinfarction, or revascularization were 7.5% versus 10.4%, respectively (P equals 0.4). 104 Facilitated PCI
Class IIb 1. Facilitated PCI might be performed as a reperfusion strategy in higher-risk patients when PCI is not immediately available and bleeding risk is low. (Level of Evidence: B)
Facilitated PCI refers to a strategy of planned immediate PCI after an initial pharmacological regimen such as full-dose fibrinolysis, half-dose fibrinolysis, a GP IIb/IIIa inhibitor, or a combination of reduced-dose fibrinolytic therapy and a platelet GP IIb/IIIa inhibitor. A strategy of facilitated PCI holds promise in higher-risk patients when PCI is not immediately available. Potential risks include increased bleeding complications, especially in patients who are at least 75 years of age (see Pharmacological Reperfusion in Section VI.C.1.f and Section 6.3.1.6.3.8. of the full-text guidelines), and potential limitations include added cost. Several randomized trials of facilitated PCI with a variety of pharmacological regimens are in progress. Rescue PCI refers to PCI within 12 hours after failed fibrinolysis for patients with continuing or recurrent myocardial ischemia.
Rescue PCI
Class
A major problem in adopting a strategy of rescue PCI lies in the limitation of accurate identification of patients for whom fibrinolytic therapy has not restored antegrade coronary flow. In a prior era in which the practice of PCI was less mature, immediate catheterization of all patients after fibrinolytic therapy to identify those with an occluded infarct artery was found to be impractical, costly, and often associated with bleeding complications. 105, 106 This strategy is being reevaluated in clinical trials testing facilitated PCI in the contemporary PCI setting.
There are no convincing data to support the routine use of late adjuvant PCI days after failed fibrinolysis or for patients who do not receive reperfusion therapy. Nevertheless, this is being done in some STEMI patients as an extension of the invasive strategy for non-STEMI patients. The Occluded Artery Trial (OAT) is currently randomizing patients to test whether routine PCI days to weeks after MI improves long-term clinical outcomes in asymptomatic high-risk patients with an occluded infarct artery. 107 Observational studies support the value of PCI for patients who develop cardiogenic shock in the early hours of STEMI. In the SHOCK trial, 75 the survival curves continued to progressively diverge such that at 6 months and 1 year, there was a significant mortality reduction with emergency revascularization (53% versus 66%, P less than 0.03). 108 The prespecified subgroup analysis of patients less than 75 years old showed an absolute 15% reduction in 30-day mortality (P less than 0.02), whereas there was no apparent benefit for the small cohort (n equals 56) of patients more than 75 years old. These data strongly support the approach that patients younger than 75 years with STEMI complicated by cardiogenic shock should undergo emergency revascularization and support measures. Three registries 109 -111 have demonstrated a marked survival benefit for elderly patients who are clinically selected for revascularization (approximately 1 of 5 patients), so age alone should not disqualify a patient from early revascularization. (See Section VII.F.5 and also Section 7.6.5 of the full-text guidelines.) Immediately After Successful Fibrinolysis. Randomized prospective trials examined the efficacy and safety of immediate PCI after fibrinolysis. 105, 106, 112 These trials showed no benefit of routine PCI of the stenotic infarct artery immediately after fibrinolytic therapy. The strategy did not appear to salvage myocardium, improve LVEF, or prevent reinfarction or death. Those subjected to this approach appeared to have an increased incidence of adverse events, including bleeding, recurrent ischemia, emergency CABG, and death. These studies have not been repeated in the modern interventional era with improved equipment, improved antiplatelet and anticoagulant strategies, and coronary stents, thus leaving the question of routine PCI early after successful fibrinolysis unresolved in contemporary practice. Studies of facilitated PCI are enrolling patients. [113] [114] [115] [116] Hours to Days After Successful Fibrinolysis. Great improvements in equipment, operator experience, and adjunctive pharmacotherapy have increased PCI success rates and decreased complications. More recently, the invasive strategy for NSTEMI patients has been given a Class I recommendation by the ACC/AHA Guidelines for the Management of Patients With Unstable Angina/Non-STEMI. 117 STEMI patients are increasingly being treated similarly as an extension of this approach. Although 6 published reports 115,118 -121,123 and 1 preliminary report 122 support this strategy, randomized studies similar to those in NSTEMI need to be performed. PATIENTS WITH STEMI NOT RECEIVING REPERFUSION Guideline-based recommendations for nonreperfusion treatments should not vary whether or not patients received reperfusion therapy. The major difference is that patients not receiving reperfusion therapy are considered to have a higher risk for future adverse events. 124 Because of the evidence that the measured effect of UFH on the aPTT is important for patient outcome and that the predominant variable mediating the effect of a given dose of heparin is weight, 125 it is important to administer the initial doses of UFH as a weight-adjusted bolus. 126 For fibrinspecific (alteplase, reteplase, and tenecteplase) fibrinolytictreated patients, a 60 U/kg bolus followed by a maintenance infusion of 12 U/kg per hour (with a maximum of 4000 U bolus and 1000 U/h initial infusion for patients weighing greater than 70 kg) is recommended. The recommended weight-adjusted dose of UFH, when it is administered without fibrinolytics, is 60 to 70 U/kg IV bolus and 12 to 15 U/kg per hour infusion. 117 The available data suggest that the rate of early (60 to 90 minutes) reperfusion of the infarct artery, either assessed angiographically or by noninvasive means, is not enhanced by administration of an LMWH. However, a generally consistent theme of a lower rate of reocclusion of the infarct artery, reinfarction, or recurrent ischemic events emerges in patients receiving LMWH regardless of whether the control group was given placebo or UFH. On the basis of the data in the HERO-2 trial, the Writing Committee believed that bivalirudin could be considered an acceptable alternative to UFH in those STEMI patients who receive fibrinolysis with streptokinase, have heparin-induced thrombocytopenia, and who, in the opinion of the treating physician, would benefit from anticoagulation.
PCI for Cardiogenic Shock
Class
Percutaneous Coronary Intervention After Fibrinolysis
ACUTE SURGICAL REPERFUSION
Class
ASSESSMENT OF REPERFUSION
LOW-MOLECULAR-WEIGHT HEPARIN AS ANCILLARY THERAPY TO REPERFUSION THERAPY
Class
DIRECT ANTITHROMBINS AS ANCILLARY THERAPY TO REPERFUSION THERAPY
Class
Antiplatelets
ASPIRIN
Class I 1. A daily dose of aspirin (initial dose of 162 to 325 mg orally; maintenance dose of 75 to 162 mg) should be given indefinitely after STEMI to all patients without a true aspirin allergy. (Level of Evidence: A)
As discussed, aspirin should be given to the patient with suspected STEMI as early as possible and should be continued indefinitely, regardless of the strategy for reperfusion and regardless of whether additional antiplatelet agents are administered. True aspirin allergy is the only exception to this recommendation. Clopidogrel combined with aspirin is recommended for STEMI patients who undergo coronary stent implantation. 128 -132 There are no safety data available regarding the combination of fibrinolytic agents and clopidogrel, but ongoing trials will provide this information in the future. However, in patients in whom aspirin is contraindicated because of aspirin sensitivity, clopidogrel is probably useful as a substitute for aspirin to reduce the risk of occlusion. 133 There are no safety data comparing 300 and 600 mg as loading doses for clopidogrel. We do not recommend routine administration of clopidogrel as pretreatment in patients who have not yet undergone diagnostic cardiac catheterization and in whom CABG surgery would be performed within 5 to 7 days if warranted. 134 
GLYCOPROTEIN IIb/IIIa INHIBITORS
Class IIa 1. It is reasonable to start treatment with abciximab as early as possible before primary PCI (with or without stenting) in patients with STEMI. (Level of Evidence: B)
Class IIb 1. Treatment with tirofiban or eptifibatide may be considered before primary PCI (with or without stenting) in patients with STEMI. (Level of Evidence: C)
The Writing Committee believes that it is reasonable to start treatment with abciximab as early as possible in patients undergoing primary PCI (with or without stenting) but, given the size and limitations of the available data set, assigned a Class IIa recommendation to this treatment. The data on tirofiban and eptifibatide in primary PCI are far more limited than for abciximab. However, given the common mode of action of the agents, a modest amount of angiographic data, 135 and general clinical experience to date, tirofiban or eptifibatide may be useful as antiplatelet therapy to support primary PCI for STEMI (with or without stenting) (Class IIb recommendation).
OTHER PHARMACOLOGICAL MEASURES
Inhibition of Renin-Angiotensin-Aldosterone System
Class I 1. An angiotensin converting enzyme (ACE) inhibitor
should be administered orally within the first 24 hours of STEMI to patients with anterior infarction, pulmonary congestion, or LVEF less than 0.40, in the absence of hypotension (systolic blood pressure less than 100 mm Hg or less than 30 mm Hg below baseline) or known contraindications to that Class of medications.
(Level of Evidence: A) 2. An angiotensin receptor blocker (ARB) should be administered to STEMI patients who are intolerant of ACE inhibitors and who have either clinical or radiological signs of heart failure or LVEF less than 0.40. Valsartan and candesartan have established efficacy for this recommendation. (Level of Evidence: C)
Class IIa
An ACE inhibitor administered orally within the first 24 hours of STEMI can be useful in patients without anterior infarction, pulmonary congestion, or LVEF less than 0.40 in the absence of hypotension (systolic blood pressure less than 100 mm Hg or less than 30 mm Hg below baseline) or known contraindications to that class of medications. The expected treatment benefit in such patients is less (5 lives saved per 1000 patients treated) than for patients with LV dysfunction. (Level of Evidence: B)
Class III 1. An intravenous ACE inhibitor should not be given to patients within the first 24 hours of STEMI because of the risk of hypotension. (A possible exception may be patients with refractory hypertension.) (Level of Evidence: B)
A number of large, randomized clinical trials have assessed the role of ACE inhibitors early in the course of acute MI. All trials with oral ACE inhibitors have shown benefit from their early use, including those in which early entry criteria included clinical suspicion of acute infarctions. Data from these trials indicate that ACE inhibitors should generally be started within the first 24 hours, ideally after fibrinolytic therapy has been completed and blood pressure has stabilized. ACE inhibitors should not be used if systolic blood pressure is less than 100 mm Hg or less than 30 mm Hg below baseline, if clinically relevant renal failure is present, if there is a history of bilateral stenosis of the renal arteries, or if there is known allergy to ACE inhibitors.
The use of ARBs has not been explored as thoroughly as ACE inhibitors in STEMI patients. However, clinical experience in the management of patients with heart failure and data from clinical trials in STEMI patients (see Sections 7.4.3 and 7.6.4 of the full-text guidelines) suggest that ARBs may be useful in patients with depressed LV function or clinical heart failure but who are intolerant of an ACE inhibitor. Use of aldosterone antagonists in STEMI patients is discussed in Sections 7.4.3 and 7.6.4 of the full-text guidelines.
Metabolic Modulation of the Glucose-Insulin Axis
STRICT GLUCOSE CONTROL DURING STEMI
Class I 1. An insulin infusion to normalize blood glucose is recommended for patients with STEMI and complicated courses. (Level of Evidence: B)
Class IIa Compelling evidence for tight glucose control in patients in the intensive care unit (a large proportion of whom were there after cardiac surgery) supports the importance of intensive insulin therapy to achieve a normal blood glucose level in critically ill patients. 136,136a Magnesium Class IIa
During the acute phase (first 24 to 48 hours) of the management of STEMI in patients with hyperglycemia, it is reasonable to administer an insulin infusion to normalize blood glucose, even in patients with
It is reasonable that documented magnesium deficits be corrected, especially in patients receiving diuretics before the onset of STEMI. (Level of Evidence: C) 2. It is reasonable that episodes of torsade de pointes-type ventricular tachycardia (VT) associated with a prolonged QT interval be treated with 1 to 2 g of magnesium administered as an intravenous bolus over 5 minutes. (Level of Evidence: C)
Class III
In the absence of documented electrolyte deficits or torsade de pointes-type VT, routine intravenous magnesium should not be administered to STEMI patients at any level of risk. (Level of Evidence: A)
Calcium Channel Blockers
Class IIa
It is reasonable to give verapamil or diltiazem to patients in whom beta-blockers are ineffective or contraindicated (eg, bronchospastic disease) for relief of ongoing ischemia or control of a rapid ventricular response with atrial fibrillation or flutter after STEMI in the absence of CHF, LV dysfunction, or atrioventricular (AV) block. (Level of Evidence: C)
Diltiazem and verapamil are contraindicated in patients with STEMI and associated systolic LV dysfunction and CHF. (Level of Evidence: A) 2. Nifedipine (immediate-release form) is contraindicated in treatment of STEMI because of the reflex sympathetic activation, tachycardia, and hypotension associated with its use. (Level of Evidence: B)
See the full-text guidelines for further explanation.
VII. Hospital Management
A. Location 
Coronary Care Unit
Class
B. Early, General Measures
Level of Activity
Class IIa 1. After 12 to 24 hours, it is reasonable to allow patients with hemodynamic instability or continued ischemia to have bedside commode privileges. (Level of Evidence: C)
Class III 1. Patients with STEMI who are free of recurrent ischemic discomfort, symptoms of heart failure, or serious disturbances of heart rhythm should not be on bed rest for more than 12 to 24 hours. (Level of Evidence: C)
Diet
Class I 1. Patients with STEMI should be prescribed the NCEP Adult Treatment Panel III (ATP III) Therapeutic Lifestyle Changes (TLC) diet, which focuses on reduced intake of fats and cholesterol, less than 7% of total calories as saturated fats, less than 200 mg of cholesterol per day, increased consumption of omega-3 fatty acids, and appropriate caloric intake for energy needs. (Level of Evidence: C) 2. Diabetic patients with STEMI should have an appropriate food group balance and caloric intake. (Level of Evidence: B) 3. Sodium intake should be restricted in STEMI patients with hypertension or heart failure. (Level of Evidence: B)
STEMI patients should receive a reduced saturated fat and cholesterol diet per the ATP III TLC approach. 137 (See VII.L.2 and Section 7.12.2 of the full-text guidelines.) Patient education should be viewed as a continuous process that should to be part of every patient encounter (ie, on hospital arrival, inpatient admission, discharge, and at follow-up visits).
Patient Education in the Hospital Setting
Analgesia/Anxiolytics
Class IIa 1. It is reasonable to use anxiolytic medications in STEMI patients to alleviate short-term anxiety or altered behavior related to hospitalization for STEMI. (Level of Evidence: C) 2. It is reasonable to routinely assess the patient's anxiety level and manage it with behavioral interventions and referral for counseling. (Level of Evidence: C)
Anxiety and depression are prevalent in patients hospitalized for STEMI because patients are confronted with a diagnosis that is major, both psychologically and physically. 138, 139 Anxiety has been demonstrated to predict in-hospital recurrent ischemia and arrhythmias 140 and cardiac events during the first year after an MI. 141
C. Risk Stratification During Early Hospital Course
Risk stratification is a continuous process and requires the updating of initial assessments with data obtained during the hospital stay. Indicators of failed reperfusion (eg, recurrence of chest pain and persistence of ECG findings indicating infarction) identify a patient who should undergo coronary angiography. Similarly, findings consistent with mechanical complications (eg, sudden onset of heart failure or presence of a new murmur) herald increased risk and suggest the need for rapid intervention. For patients who did not undergo primary reperfusion, changes in clinical status (eg, development of shock) may herald a worsening clinical status and are an indication for coronary angiography. Patients with a low risk of complications may be candidates for early discharge. The lowest-risk patients are those who did not have STEMI despite the initial suspicions. Clinicians should strive to identify such patients within 8 to 12 hours of onset of symptoms. Serial sampling of serum cardiac biomarkers and use of 12-lead ECGs and their interpretation in the context of the number of hours that have elapsed since onset of the patient's symptoms can determine the presence of STEMI better than adherence to a rigid protocol that requires that a specified number of samples be drawn in the hospital.
D. Medication Assessment
Beta-Blockers
Class I 1. Patients receiving beta-blockers within the first 24 hours of STEMI without adverse effects should continue to receive them during the early convalescent phase of STEMI. (Level of Evidence: A) 2. Patients without contraindications to beta-blockers who did not receive them within the first 24 hours after STEMI should have them started in the early convalescent phase. (Level of Evidence: A) 3. Patients with early contraindications within the first 24 hours of STEMI should be reevaluated for candidacy for beta-blocker therapy. (Level of Evidence: C)
There is overwhelming evidence for the benefits of early beta-blockade in patients with STEMI and without contraindications to their use (see Section 6.3.1.5 of the full-text guidelines). Benefits have been demonstrated for patients with and without concomitant fibrinolytic therapy, both early and late after STEMI. Meta-analysis of trials from the prefibrinolytic era involving more than 24 000 patients receiving beta-blockers have shown a 14% relative risk reduction in mortality through 7 days and a 23% reduction in long-term mortality. 142 
Nitroglycerin
Class I 1. Intravenous nitroglycerin is indicated in the first 48 hours after STEMI for treatment of persistent ischemia, CHF, or hypertension. The decision to administer intravenous nitroglycerin and the dose used should not preclude therapy with other proven mortalityreducing interventions, such as beta-blockers or ACE inhibitors. (Level of Evidence: B) 2. Intravenous, oral, or topical nitrates are useful beyond the first 48 hours after STEMI for treatment of recurrent angina or persistent CHF if their use does not preclude therapy with beta-blockers or ACE inhibitors. (Level of Evidence: B)
Class IIb 1. The continued use of nitrate therapy beyond the first 24 to 48 hours in the absence of continued or recurrent angina or CHF may be helpful, although the benefit is likely to be small and is not well established in contemporary practice. (Level of Evidence: B)
Class III 1. Nitrates should not be administered to patients with systolic pressure less than 90 mm Hg or greater than or equal to 30 mm Hg below baseline, severe bradycardia (less than 50 bpm), tachycardia (more than 100 bpm) or RV infarction. (Level of Evidence: C) The use of ACE inhibitors in the initial management of the STEMI patient was reviewed previously. The proportional benefit of ACE inhibitor therapy is largest in higher-risk subgroups, including those with previous infarction, heart failure, depressed LVEF, and tachycardia. [143] [144] [145] Survival benefit for patients more than 75 years old and for a low-risk subgroup without the features noted above is equivocal. 144, 145 Aldosterone blockade is another means of inhibiting the renin-angiotensin-aldosterone system that has been applied to patients in the post-STEMI setting. RALES (Randomized Aldactone Evaluation Study) and EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) support the long-term use of an aldosterone blocker in STEMI patients with heart failure, an ejection fraction of 0.40 or less, or both, provided the serum creatinine is less than or equal to 2.5 mg/dL in men and less than or equal to 2.0 mg/dL in women and serum potassium concentration is less than or equal to 5.0 mEq/L. 146, 147 The use of ARBs after STEMI has not been explored as thoroughly as ACE inhibitors in STEMI patients. 148, 149 Given the extensive randomized trial and routine clinical experience with ACE inhibitors, they remain the logical first agent for inhibition of the renin-angiotensin-aldosterone system in patients convalescing from STEMI. 150 Valsartan monotherapy (target dose 160 mg twice daily) should be administered to STEMI patients who are intolerant of ACE inhibitors and have evidence of LV dysfunction. Valsartan monotherapy can be a useful alternative to ACE inhibitors; the decision in individual patients may be influenced by physician and patient preference, cost, and anticipated side-effect profile. 
Inhibition of the Renin-Angiotensin-Aldosterone System
Class
Antiplatelets
Class I 1. Aspirin 162 to 325 mg should be given on day 1 of STEMI and in the absence of contraindications should be continued indefinitely on a daily basis thereafter at
Antithrombotics
Class I 1. Intravenous UFH (bolus of 60 U/kg, maximum 4000 U IV; initial infusion 12 U/kg per hour, maximum of 1000 U/h) or LMWH should be used in patients after STEMI who are at high risk for systemic emboli (large or anterior MI, atrial fibrillation, previous embolus, known LV thrombus, or cardiogenic shock). (Level of Evidence: C)
Class IIa 1. It is reasonable that STEMI patients not undergoing reperfusion therapy who do not have a contraindication to anticoagulation be treated with intravenous or subcutaneous UFH or with subcutaneous LMWH for at least 48 hours. In patients whose clinical condition necessitates prolonged bedrest and/or minimized activities, it is reasonable that treatment be continued until the patient is ambulatory. (Level of Evidence: C)
Class IIb 1. Prophylaxis for deep venous thrombosis (DVT) with subcutaneous LMWH (dosed appropriately for specific agent) or with subcutaneous UFH, 7500 U to 12 500 U twice per day until completely ambulatory, may be useful, but the effectiveness of such a strategy is not well
E. Estimation of Infarct Size
Measurement of infarct size is an important element in the overall care of patients with STEMI. There are 5 major modalities that can be applied to sizing MI.
Electrocardiographic Techniques
Class I 1. All patients with STEMI should have follow-up ECGs at 24 hours and at hospital discharge to assess the success of reperfusion and/or the extent of infarction, defined in part by the presence or absence of new Q waves. (Level of Evidence: B) 
Cardiac Biomarker Methods
The most widely accepted method for quantifying infarction has been the use of serial creatine kinase and the creatine kinase-MB isoenzyme.
Radionuclide Imaging
The most comprehensive assessment of STEMI with radionuclide imaging was developed with the technetium sestamibi SPECT approach. 151 This approach is well delineated in the ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging. 152
Echocardiography
Global and regional LV function provides an assessment of the functional consequences of STEMI and ischemia. Readers are referred to the ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography 153 and to Section 7.11.1.2 of the full-text STEMI guidelines.
Magnetic Resonance Imaging
Measurement of infarct size by MRI is a promising new technique that affords enhanced spatial resolution, thereby permitting more accurate assessment of both the transmural and circumferential extent of infarction. 154 However, additional experience and comparison with other methods of assessing infarct size are required before any clinical recommendations can be provided. 
F. Hemodynamic Disturbances
Hemodynamic Assessment
Hypotension
Class I 1. Rapid volume loading with an IV infusion should be administered to patients without clinical evidence for volume overload. (Level of Evidence: C) 2. Rhythm disturbances or conduction abnormalities causing hypotension should be corrected. (Level of Evidence: C) 3. Intra-aortic balloon counterpulsation should be performed in patients who do not respond to other interventions, unless further support is futile because of the patient's wishes or contraindications/unsuitability for
Class III 1. Beta-blockers or calcium channel antagonists should not be administered to patients in a low-output state due to pump failure. (Level of Evidence: B)
A preshock state of hypoperfusion with normal blood pressure may develop before circulatory collapse and is manifested by cold extremities, cyanosis, oliguria, or decreased mentation. 155 Hospital mortality is high, so these patients should be aggressively diagnosed and treated as though they had cardiogenic shock. The initial pharmacological intervention for low cardiac output is often a dobutamine infusion. Intra-aortic counterpulsation therapy may be required to improve coronary artery perfusion pressure if hypotension is present. If the blood pressure permits, afterload-reducing agents should be added to decrease cardiac work and pulmonary congestion. Coronary artery revascularization of ischemic myocardium with either PCI or CABG has been shown to decrease mortality in patients with cardiogenic shock and is strongly recommended in suitable candidates. 75, 108 Likewise, patients with VSR, papillary muscle rupture, or free wall rupture with pericardial tamponade may benefit from emergency surgical repair.
Pulmonary Congestion
Class I 1. Oxygen supplementation to arterial saturation greater than 90% is recommended for patients with pulmonary congestion. (Level of Evidence: C) 2. Morphine sulfate should be given to patients with pulmonary congestion. (Level of Evidence: C) 3. ACE inhibitors, beginning with titration of a short-
acting ACE inhibitor with a low initial dose (eg, 1 to 6.25 mg of captopril) should be given to patients with pulmonary edema unless the systolic blood pressure is less than 100 mm Hg or more than 30 mm Hg below baseline. Patients with pulmonary congestion and marginal or low blood pressure often need circulatory support with inotropic and vasopressor agents and/or intra-aortic balloon counterpulsation to relieve pulmonary congestion and maintain adequate perfusion. (Level of Evidence: A) The immediate management goals include adequate oxygenation and preload reduction to relieve pulmonary congestion. Because of sympathetic stimulation, the blood pressure should be elevated in the presence of pulmonary edema. Patients with this appropriate response can typically tolerate the required medications, all of which lower blood pressure. However, iatrogenic cardiogenic shock may result from aggressive simultaneous use of agents that cause hypotension, initiating a cycle of hypoperfusion-ischemia. If acute pulmonary edema is not associated with elevation of the systemic blood pressure, impending cardiogenic shock must be suspected. If pulmonary edema is associated with hypotension, cardiogenic shock is diagnosed. Those patients often need circulatory support with inotropic and vasopressor agents and/or intra-aortic balloon counterpulsation to relieve pulmonary congestion and maintain adequate perfusion (Figure 4 ) (See Section VII.F.5, and see Section 7.6.5 of the full-text guidelines). Given the large overall treatment benefit of 13 lives saved per 100 patients treated in the SHOCK trial, early revascularization is recommended for those less than 75 years who are suitable for revascularization. 75, 108, 156 Two other large registries reported a substantial survival benefit for elderly patients who were selected clinically on the basis of physician judgment.
Nitrates should be administered to patients with pulmonary congestion unless the systolic blood pressure is less than 100 mm Hg or more than 30 mm Hg below baseline. Patients with pulmonary congestion and marginal or low blood pressure often need circulatory support with inotropic and vasopressor agents and/or intra-aortic balloon counterpulsation to relieve pulmo-
Cardiogenic Shock
Class I 1. Intra-aortic balloon counterpulsation is recommended for STEMI patients when cardiogenic shock
Interventions should be performed as soon as possible. It is recommended that patients who arrive at the hospital in cardiogenic shock (15% of cases) or who develop it after hospital arrival (85%) should be transferred to a regional tertiary care center with revascularization facilities experienced with these patients. When shock has resolved, ACE inhibitors and beta-blockers, initiated in low doses with progressive increases as recommended in the CHF guidelines, should be administered before discharge. 157 (See Section 7.6.7.6 of the full-text guidelines for discussion of mechanical support for the failing heart.) 
Right Ventricular Infarction
Class I 1. Patients with inferior STEMI and hemodynamic compromise should be assessed with a right precordial V 4 R lead to detect ST-segment elevation and an echocardio-
Class IIa 1. After infarction that leads to clinically significant RV dysfunction, it is reasonable to delay CABG surgery for 4 weeks to allow recovery of contractile performance. (Level of Evidence: C)
Treatment of RV ischemia/infarction includes early maintenance of RV preload, reduction of RV afterload, inotropic support of the dysfunctional RV, early reperfusion, 158 and maintenance of AV synchrony.
Mechanical Causes of Heart Failure/Low-Output Syndrome
a. Diagnosis
On physical examination, the presence of a new cardiac murmur indicates the possibility of either a VSR or MR. A precise diagnosis can usually be established with transthoracic or transesophageal echocardiography.
b. Mitral Valve Regurgitation
Class I 1. Patients with acute papillary muscle rupture should be considered for urgent cardiac surgical repair, unless further support is considered futile because of the Insertion of an IABP and prompt surgical referral are recommended for almost every patient with an acute VSR. Invasive monitoring is recommended in all patients, together with judicious use of inotropes and a vasodilator to maintain optimal hemodynamics. Surgical repair usually involves excision of all necrotic tissue and patch repair of the VSR, together with coronary artery grafting. Selected patients with cardiogenic shock after STEMI, especially if not candidates for revascularization, may be considered for either a short-or long-term mechanical support device to serve as a bridge to recovery or to subsequent cardiac transplantation. There is no convincing evidence that the prophylactic use of lidocaine reduces mortality, and the prior practice of routine (prophylactic) administration of lidocaine to all patients with known or suspected STEMI has been largely abandoned. VF should be treated with an unsynchronized electric shock using an initial monophasic shock energy of 200 J. If this is unsuccessful, a second shock using 200 to 300 J and, if necessary, a third shock using 360 J are indicated. 160 Management Strategies for VT. Cardioversion is always indicated for episodes of sustained hemodynamically compromising VT. 161 Episodes of sustained VT that are somewhat better tolerated hemodynamically may initially be treated with drug regimens, including amiodarone or procainamide.
d. Left Ventricular Free-Wall Rupture
G. Arrhythmias After STEMI
Ventricular Arrhythmias a. Ventricular Fibrillation
b. Ventricular Tachycardia
c. Ventricular Premature Beats
Class III 1. Treatment of isolated ventricular premature beats, couplets, and nonsustained VT is not recommended unless they lead to hemodynamic compromise. (Level of Evidence: A)
Before the present era of care of the STEMI patient with antiplatelet therapy, beta-blockade, ACE inhibitors, and, above all, reperfusion strategies, it was thought that ventricular warning arrhythmias preceded VF. Careful monitoring has refuted this concept, and treatment of these rhythm disturbances is not recommended unless they lead to hemodynamic compromise. See the full-text guidelines for discussion. 
d. Accelerated Idioventricular Rhythms and Accelerated Junctional Rhythms
Class
Supraventricular Arrhythmias/Atrial Fibrillation
Class
Normal Action Class Action Class Action Class Action Class Action Class Action Class Action Class
Observe A  TC  TV   I  III  III  III   Observe  A  TC  TV   I  III  IIb  III   Observe  A  TC  TV   I  III  IIb  III   Observe  A*  TC  TV   IIb  III  I  III   Observe  A  TC  TV   IIa  III  I  III   Observe  A  TC  TV   III  III  I  IIa   Observe  A  TC  TV   III  III Observe  A  TC  TV   III  III  I  IIb   Observe  A  TC  TV   III  III  I  IIa   Observe  A  TC  TV   III  III  I  IIa   Observe  A*  TC  TV   III  III  I  IIa   Observe  A  TC  TV   III  III  I  IIa   Observe  A  TC  TV   III  III  IIb  I   Observe  A  TC  TV   III  III IIb I
Alternating left and right bundle-branch block
Observe A  TC  TV   III  III  IIb  I   Observe  A  TC  TV   III  III  IIb  I   Observe  A  TC  TV   III  III  IIb  I   Observe  A*  TC  TV   III  III  IIb  I   Observe  A  TC  TV   III  III  IIb  I   Observe  A  TC  TV   III  III  IIb  I   Observe  A  TC  TV   III  III  IIb  I   This table is designed to summarize the atrioventricular (column headings) and intraventricular (row headings) conduction disturbances that may occur during acute anterior or nonanterior STEMI, the possible treatment options, and the indications for each possible therapeutic option.
LAFB indicates left anterior fascicular block; LPFB, left posterior fascicular block; RBBB, right bundle-branch block; A, atropine; TC, transcutaneous pacing; TV, temporary transvenous pacing; STEMI, ST elevation myocardial infarction; AV, atrioventricular; and MI, myocardial infarction.
Action There are 4 possible actions, or therapeutic options, listed and classified for each bradyarrhythmia or conduction problem: 1. Observe: continued ECG monitoring, no further action planned. 2. A, and A*: atropine administered at 0.6 to 1.0 mg IV every 5 minutes to up to 0.04 mg/kg. In general, because the increase in sinus rate with atropine is unpredictable, this is to be avoided unless there is symptomatic bradycardia that will likely respond to a vagolytic agent, such as sinus bradycardia or Mobitz I, as denoted by the asterisk, above.
3. TC: application of transcutaneous pads and standby transcutaneous pacing with no further progression to transvenous pacing imminently planned. 4. TV: temporary transvenous pacing. It is assumed, but not specified in the table, that at the discretion of the clinician, transcutaneous pads will be applied and standby transcutaneous pacing will be in effect as the patient is transferred to the fluoroscopy unit for temporary transvenous pacing.
Class Each possible therapeutic option is further classified according to ACC/AHA criteria as I, IIa, IIb, and III.
Level of Evidence
This table was developed from (1) published observational case reports and case series, (2) published summaries, not meta-analyses, of these data; and (3) expert opinion, largely from the prereperfusion era. There are no published randomized trials comparing different strategies of managing conduction disturbances after STEMI. Thus, the level of evidence for the recommendations in this table is C.
How to Use the The role of surgical revascularization has been reviewed extensively in the ACC/AHA Guidelines for CABG Surgery. 166 Consideration for revascularization after STEMI includes PCI and CABG. Providers should individualize patient management on the basis of clinical circumstances, available revascularization options, and patient preference. STEMI patients undergoing revascularization frequently receive 1 or more antiplatelet agents and heparin, all of which may increase risk of serious bleeding during and after cardiac surgery. Delaying surgery until platelet function has recovered may not be feasible in many circumstances. In patients treated with the small-molecule GP IIb/IIIa receptor antagonists, tirofiban and eptifibatide, platelet function returns toward normal within 4 hours of stopping treatment. Platelet aggregation does not return toward normal for more than 48 hours in patients treated with abciximab. Management strategies, other than delaying surgery, include platelet transfusions for patients who were recently treated with abciximab, reduced heparin dosing during cardiopulmonary bypass, and possible use of antifibrinolytic agents such as aprotinin or tranexamic acid. 167 Because clopidogrel, when added to aspirin, increases the risk of bleeding during major surgery in patients who are scheduled for elective CABG, clopidogrel should be withheld for at least 5 days 168 and preferably for 7 days before surgery. 169 Figure 6 . Evidence-based approach to need for catheterization (cath) and revascularization after STEMI. This algorithm shows treatment paths for patients who initially undergo a primary invasive strategy, receive fibrinolytic therapy, or do not undergo reperfusion therapy for STEMI. Patients who have not undergone a primary invasive strategy and have no high-risk features should undergo functional evaluation with one of the noninvasive tests shown. When clinically significant ischemia is detected, patients should undergo catheterization and revascularization as indicated; if no clinically significant ischemia is detected, medical therapy is prescribed after STEMI. *Please see Table 23 of the ACC/AHA Guidelines for the Management of Patients With Chronic Stable Angina for further definition. †Please see Table 3 , Section 6.3.1.6.2., and Section 7.3. in the full-text STEMI guidelines for further discussion. STEMI indicates ST-elevation myocardial infarction; EF, ejection fraction; ECG, electrocardiography. LDL-C substantially less than 100 mg/dL (baseline or on-treatment):
Elective CABG Surgery After STEMI in Patients With Angina
CABG Surgery After STEMI and Antiplatelet Agents
• Statins should be used to lower LDL-C.
LDL-C greater than or equal to 100 mg/dL (baseline or on-treatment):
• Intensify LDL-C-lowering therapy with drug treatment, giving preference to statins. If waist circumference is greater than or equal to 35 inches in women or greater than or equal to 40 inches in men, initiate lifestyle changes and treatment strategies for metabolic syndrome.
Diabetes management: Goal HbA1c less than 7% Appropriate hypoglycemic therapy to achieve near-normal fasting plasma glucose, as indicated by HbA1c. Treatment of other risks (eg, physical activity, weight management, blood pressure, and cholesterol management).
Antiplatelet agents/anticoagulants:
Start and continue indefinitely aspirin 75 to 162 mg/d if not contraindicated. Consider clopidogrel 75 mg/d or warfarin if aspirin is contraindicated. Manage warfarin to INR of 2.5 to 3.5 in post-STEMI patients when clinically indicated or for those not able to take aspirin or clopidogrel (Figure 7) .
Renin-Angiotensin-Aldosterone System Blockers:
ACE inhibitors in all patients indefinitely; start, early in stable high-risk patients (anterior MI, previous MI, Killip class greater than or equal to II ͓S 3 gallop, rales, radiographic CHF͔, LVEF less than 0.40). ARBs in patients who are intolerant of ACE inhibitors and who have either clinical or radiological signs of heart failure or LVEF less than 0.40. Aldosterone blockade in patients without significant renal dysfunction § or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor, have an LVEF less than or equal to 0.40, and have either diabetes or heart failure.
Beta-Blockers:
Start in all patients. Continue indefinitely. Observe usual contraindications. On the basis of 12 randomized trials in 18 788 patients with prior infarction, the Antiplatelet Trialists' Collaboration reported a 25% reduction in the risk of recurrent infarction, stroke, or vascular death in patients receiving prolonged antiplatelet therapy (36 fewer events for every 1000 patients treated). 31 No antiplatelet therapy has proved superior to aspirin in this population, and daily doses of aspirin between 80 and 325 mg appear to be effective. 184 The CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) trial, which compared aspirin with clopidogrel in 19 185 patients at high risk for vascular events, demonstrated a modest but significant (8.6%, P equals 0.043) reduction in serious vascular events with clopidogrel compared with aspirin. 185 These data suggest clopidogrel as the best alternative to aspirin in patients with true aspirin allergy.
The use of warfarin therapy for secondary prevention of vascular events in patients after STEMI is discussed in Section 7.12.11 of the full-text guidelines. Large randomized trials have demonstrated that oral anticoagulants, when given in adequate doses, reduce the rates of adverse outcomes, at the cost of a small increase in hemorrhagic events. 186 -188 In the Warfarin, Aspirin, Reinfarction Study (WARIS II), warfarin without aspirin in a dose intended to achieve an INR of 2.8 to 4.2 resulted in a significant reduction in a composite end point (death, nonfatal reinfarction, or thromboembolic stroke) compared with therapy with aspirin alone (16.7% versus 20.0%). 186 Warfarin therapy resulted in a small but significant increase in major, nonfatal bleeding compared with therapy with aspirin alone (0.62% versus 0.17% per year). Chronic therapy with warfarin after STEMI presents an alternative to clopidogrel in patients with aspirin allergy. The use of ACE inhibitors early in the acute phase of STEMI and in the hospital management phase has been described earlier.
Inhibition of Renin-Angiotensin-Aldosterone-System
Class
Compelling evidence now supports the broad long-term use of ACE inhibitors after STEMI. 189, 190 The results of the VALIANT study (Valsartan in Acute Myocardial Infarction Trial) evaluating valsartan are discussed in Section 7.4.3 of the full-text guidelines. The series of CHARM studies (Candesartan in Heart Failure Assessment in Reduction of Mortality), although focusing on the evaluation of candesartan in patients with chronic heart failure, provides information that can be extrapolated to the long-term management of the STEMI patient, because 50% to 60% of the patients studied had ischemic heart disease as the cause of heart failure. [191] [192] [193] Given the extensive randomized trial and routine clinical experience with ACE inhibitors, they remain the logical first agent for inhibition of the renin-angiotensin-aldosterone system in the long-term management of patients with STEMI. 150, 194 The ARBs valsartan and candesartan should be administered over the long term to STEMI patients with symptomatic heart failure who are intolerant of ACE inhibitors. As described in Section 7.4.3 of the full-text guidelines, the choice between an ACE inhibitor and an ARB over the long term in patients who are tolerant of ACE inhibitors will vary with individual physician and patient preference, as well as cost and anticipated side-effect profile. 150, 194 The results of the most relevant clinical trials that tested combinations of ACE inhibitors and ARBs have been subtly different, but clinically relevant. Whereas the CHARM-Added 192 trial demonstrated a reduction in the combined end point of heart failure hospitalization and death over ACE inhibition alone, the VALIANT study 149 reported that the combination of captopril and valsartan was equivalent to either alone, but with a greater number of adverse effects. Thus, when combination ACE inhibition and angiotensin receptor blockade is considered necessary, the preferred ARB is candesartan. Although there is evidence that the combination of an ACE inhibitor and an aldosterone inhibitor is effective at reducing mortality and is well tolerated in patients with a serum creatinine level of 2.5 mg/dL or less and a serum potassium concentration of 5.0 mEq/L or less (see Section 7.4.3 of the full-text guidelines), much less experience exists with the combination of an ARB and aldosterone inhibitor (24% of 2028 patients in the CHARM-Alternative trial) 191 and the triple combination of an ACE inhibitor, ARB, and an aldosterone antagonist (17% of 2548 patients in the CHARM-Added trial). 192 The combination of an ACE inhibitor and an ARB (valsartan 20 mg/d orally initially; titrated up to 160 mg orally twice per day, or candesartan 4 to 8 mg/d orally initially; titrated up to 32 mg/d orally) or an ACE inhibitor and an aldosterone inhibitor may be considered for the long-term management of STEMI patients with symptomatic heart failure and LVEF less than 0.40, provided the serum creatinine level is less than or equal to 2.5 mg/dL in men and less than or equal to 2.0 mg/dL in women and the serum potassium concentration is less than or equal to 5.0 mEq/L (See Sections 7.4.3 and 7.6.4 of the full-text guidelines.) The use of beta-blockers in the early phase of STEMI and in hospital management is reviewed in Sections 6.3.1.6 and 7.4.1 of the full-text guidelines. The benefits of beta-blocker therapy in patients without contraindications have been demonstrated with or without reperfusion, initiated early or later in the clinical course, and for all age groups. The benefits of beta-blocker therapy for secondary prevention are well established. 142, 196 In patients with moderate or severe LV failure, beta-blocker therapy should be administered with a gradual titration scheme. 197 Long-term beta-blocker therapy should be administered to survivors of STEMI who have subsequently undergone revascularization, because there is evidence of a mortality benefit from their use despite revascularization with either CABG surgery or PCI. 198 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) 199 recommends that patients be treated after MI with ACE inhibitors, beta-blockers, and, if necessary, aldosterone antagonists to a target blood pressure of less than 140/90 mm Hg, or less than 130/80 mm Hg for those with chronic kidney disease or diabetes. 199 Most patients will require 2 or more drugs to reach this goal, and when the blood pressure is greater than 20/10 mm Hg above goal, 2 drugs should usually be used from the outset. JNC-7 emphasizes the importance of lifestyle modifications for all patients with blood pressure of 120/80 mm Hg or recovering from STEMI to prevent cardiovascular disease.
Beta-Blockers
Class
Blood Pressure Control
Class
(Level of Evidence: A)
There is no convincing evidence to support lipid-or water-soluble antioxidant supplementation in patients after STEMI or patients with or without established coronary disease.
VIII. Long-Term Management
A. Psychosocial Impact of STEMI
Class I 1. The psychosocial status of the patient should be evaluated, including inquiries regarding symptoms of depression, anxiety, or sleep disorders and the social support environment. (Level of Evidence: C)
Class IIa 1. Treatment with cognitive-behavioral therapy and selective serotonin reuptake inhibitors can be useful for STEMI patients with depression that occurs in the year after hospital discharge. (Level of Evidence: A)
Treatment of depression with combined cognitivebehavioral therapy and selective serotonin reuptake inhibitors improves outcome in terms of depression symptoms and social function. 204 -206 It appears prudent to assess STEMI patients for depression during hospitalization and during the first month after STEMI and to intervene and reassess yearly in the first 5 years, as appropriate. There is evidence that the STEMI experience, with its sudden and unexpected onset, dramatic changes in lifestyle, and the additive effort of comorbid life events, is a relatively traumatic event and may produce impaired coping during subsequent ischemic events. 207 . Long-term antithrombotic therapy at hospital discharge after STEMI. ASA indicates aspirin; LOE, level of evidence LV, left ventricular; and INR, international normalized ratio. *Clopidogrel is preferred over warfarin because of increased risk of bleeding and low patient compliance in warfarin trials. †For 12 months. ‡Discontinue clopidogrel 1 month after implantation of a bare metal stent or several months after implantation of a drug-eluting stent (3 months after sirolimus and 6 months after paclitaxel) because of the potential increased risk of bleeding with warfarin and 2 antiplatelet agents. Continue aspirin and warfarin long term if warfarin is indicated for other reasons such as atrial fibrillation, LV thrombus, cerebral emboli, or extensive regional wall-motion abnormality. §An INR of 2.0 to 3.0 is acceptable with tight control, but the lower end of this range is preferable. The combination of antiplatelet therapy and warfarin may be considered in patients aged less than 75 years with low bleeding risk who can be monitored reliably.
B. Cardiac Rehabilitation
